Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects

被引:26
作者
Kozawa, O
Uematsu, T
Matsuno, H
Niwa, M
Takiguchi, Y
Matsumoto, S
Minamoto, M
Niida, Y
Yokokawa, M
Nagashima, S
Kanamaru, M
机构
[1] Gifu Univ, Sch Med, Dept Pharmacol, Gifu 500, Japan
[2] Univ Tokushima, Grad Sch Pharmaceut Sci, Dept Clin Pharmacol, Tokushima 770, Japan
[3] Lederle Japan Ltd, Tokyo 175, Japan
[4] Shitoro Clin, Hamamatsu, Shizuoka 432, Japan
关键词
D O I
10.1128/AAC.42.6.1433
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The pharmacokinetics and tolerability of a new parenteral carbapenem antibiotic, biapenem (L-627), were studied in healthy elderly volunteers aged 65 to 73 years (71.6 +/- 2.7 years [mean +/- standard deviation], n = 5; group B) and greater than or equal to 75 years (77.8 +/- 1.9 years, n = 5; group C), following single intravenous doses (300 and 600 mg), and compared with those of healthy young male volunteers aged 20 to 29 years (23.0 +/- 3.5 years, n = 5; group A). The agent was well tolerated in all three age groups, Serial blood and urine samples were analyzed for biapenem to obtain key pharmacokinetic parameters by both two-compartment model-dependent and -independent methods. The maximum plasma concentration and area under plasma concentration-versus-time curve (AUC) increased in proportion to the dose in all three groups. Statistically significant age-related effects for AUC, total body clearance, and renal clearance (CLR) were found, while elimination half-life (t(1/2 beta)) and percent cumulative recovery from urine of unchanged drug (% UR) remained unaltered (t(1/2 beta), 1.51 +/- 0.42 [300 mg] and 2.19 +/- 0.64 [600 mg] h [group A], 1.82 +/- 1.14 and 1.45 +/- 0.36 h [group B], and 1.75 +/- 0.23 and 1.59 +/- 0.18 h [group C]; %UR, 52.6% +/- 3.0% [300 mg] and 53.1% +/- 5.1% [600 mg] [group 4], 46.7% +/- 7.4% and 53.0% +/- 4.8% [group B], and 50.1% +/- 5.2% and 47.1% +/- 7.6% [group C]), A significant linear correlation was observed between the CLR of biapenem and creatinine clearance at the dose of 300 mg but not at 600 mg, The steady-state volume of distribution tended to be decreased with age, although not significantly. Therefore, the age-related changes in parameters of biapenem described above were attributable to the combination of decreased lean body mass and lowered renal function of the elderly subjects. However, the magnitude of those changes does not necessitate dosage adjustment in elderly patients with normal renal function for their age.
引用
收藏
页码:1433 / 1436
页数:4
相关论文
共 17 条
[1]   ADVERSE-EFFECTS OF MONOBACTAMS AND CARBAPENEMS [J].
ALVAN, G ;
NORD, CE .
DRUG SAFETY, 1995, 12 (05) :305-313
[2]   EFFECTS OF AGE AND GENDER ON PHARMACOKINETICS OF CEFEPIME [J].
BARBHAIYA, RH ;
KNUPP, CA ;
PITTMAN, KA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (06) :1181-1185
[3]   PHARMACOKINETIC STUDIES IN ELDERLY PEOPLE - ARE THEY NECESSARY [J].
CROME, P ;
FLANAGAN, RJ .
CLINICAL PHARMACOKINETICS, 1994, 26 (04) :243-247
[4]  
CROWLEY J, 1990, RATIONAL THERAPEUTIC, P141
[5]   ADULT LEAN BODY MASS DECLINES WITH AGE - SOME LONGITUDINAL OBSERVATIONS [J].
FORBES, GB ;
REINA, JC .
METABOLISM, 1970, 19 (09) :653-&
[6]   RENAL DEHYDROPEPTIDASE-I STABILITY OF LJC 10,627, A NEW CARBAPENEM ANTIBIOTIC [J].
HIKIDA, M ;
KAWASHIMA, K ;
NISHIKI, K ;
FURUKAWA, Y ;
NISHIZAWA, K ;
SAITO, I ;
KUWAO, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (02) :481-483
[7]   Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects [J].
Kozawa, O ;
Uematsu, T ;
Matsuno, H ;
Niwa, M ;
Nagashima, S ;
Kanamaru, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) :2824-2828
[8]   CLINICAL PHARMACOKINETICS OF ANTIBACTERIAL DRUGS IN THE ELDERLY - IMPLICATIONS FOR SELECTION AND DOSAGE [J].
MEYERS, BR ;
WILKINSON, P .
CLINICAL PHARMACOKINETICS, 1989, 17 (06) :385-395
[9]  
NAKASHIMA M, 1993, INT J CLIN PHARM TH, V31, P70
[10]  
NORRBY SR, 1995, MED CLIN N AM, V79, P745